The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
The severity of lung disease in preterm infants with bronchopulmonary dysplasia and pulmonary hypertension undergoing cardiac catheterization did not correlate with mortality.
Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.
The neural network developed in this study yielded a false-negative rate of 0.22%.
Investigators examined a link between major cardiovascular risk factors, such as older age and smoking, and venous thromboembolism, consisting of deep vein thrombosis or pulmonary embolism.
Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.
The American Society of Hematology has developed new guidelines for the treatment of venous thromboembolism.
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo.
The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.